Mechanisms of Osimertinib Resistance in EGFR Mutant Lung Cancer

被引：0
|
作者：
Westover, D. [1 ]
Qiao, H. [1 ]
Ichihara, E. [1 ]
Meador, C. B. [1 ]
Lovly, C. M. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 08期
关键词：
D O I：
10.1016/j.jtho.2017.06.063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1546 / S1546
页数：1
相关论文
共 50 条
  • [41] Acquired Resistance to Afatinib in EGFR- Mutant Lung Cancer
    Sequist, L. V.
    Gerber, D. E.
    Fidias, P.
    Shaw, A. T.
    Temel, J. S.
    Heist, R. S.
    Gainor, J. F.
    Fulton, L.
    Kennedy, E. A.
    Muzikansky, A.
    Engelma, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S43 - S44
  • [42] Overcoming therapy resistance in EGFR-mutant lung cancer
    Antonio Passaro
    Pasi A. Jänne
    Tony Mok
    Solange Peters
    Nature Cancer, 2021, 2 : 377 - 391
  • [43] PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY IN EGFR MUTANT LUNG CANCER BRAIN METASTASIS
    Thapa, Bicky
    Chao, Samuel
    Pennell, Nathan
    Peereboom, David
    Ahluwalia, Manmeet
    NEURO-ONCOLOGY, 2018, 20 : 54 - 54
  • [44] A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed
    Takano, Natsuki
    Seike, Masahiro
    Sugano, Teppei
    Matsuda, Kuniko
    Hisakane, Kakeru
    Yoshikawa, Akiko
    Nakamichi, Shinji
    Noro, Rintaro
    Gemma, Akihiko
    ANTICANCER RESEARCH, 2022, 42 (02) : 709 - 722
  • [45] Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer
    Chen, Zhen
    Vallega, Karin A.
    Wang, Dongsheng
    Quan, Zihan
    Fan, Songqing
    Wang, Qiming
    Leal, Ticiana
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    JOURNAL OF EXPERIMENTAL MEDICINE, 2024, 221 (11):
  • [46] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [47] Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
    Le, Xiuning
    Puri, Sonam
    Negrao, Marcelo V.
    Nilsson, Monique B.
    Robichaux, Jacqulyne
    Boyle, Theresa
    Hicks, J. Kevin
    Lovinger, Katherine L.
    Roarty, Emily
    Rinsurongkawong, Waree
    Tang, Ming
    Sun, Huiying
    Elamin, Yasir
    Lacerda, Lara C.
    Lewis, Jeff
    Roth, Jack A.
    Swisher, Stephen G.
    Lee, J. Jack
    William, William N., Jr.
    Glisson, Bonnie S.
    Zhang, Jianjun
    Papadimitrakopoulou, Vassiliki A.
    Gray, Jhanelle E.
    Heymach, John V.
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6195 - 6203
  • [48] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
  • [49] Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
    Schoenfeld, Adam J.
    Chan, Joseph M.
    Kubota, Daisuke
    Sato, Hiroki
    Rizvi, Hira
    Daneshbod, Yahya
    Chang, Jason C.
    Paik, Paul K.
    Offin, Michael
    Arcila, Maria E.
    Davare, Monika A.
    Shinde, Ujwal
    Pe'er, Dana
    Rekhtman, Natasha
    Kris, Mark G.
    Somwar, Romel
    Riely, Gregory J.
    Ladanyi, Marc
    Yu, Helena A.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2654 - 2663
  • [50] EGFR Mutant Lung Cancer
    Gong, Yixuan
    Pao, William
    THERAPEUTIC KINASE INHIBITORS, 2012, 355 : 59 - 81
12345